A phase II trial of Gemzar (gemcitabine) and Gleevec (imatinib mesylate) in patients with metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2014
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Renal cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status change from in progress to completed.